Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.
At CADTH, input is information, insight, or advice given to CADTH to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.
Draft Recommendations
patiromer (Veltassa)
Therapeutic Area: Hyperkalemia, adults (chronic kidney disease)
Draft recommendations posted for stakeholder feedback: May 13, 2021
End of feedback period: May 28, 2021
Draft Recommendation
semaglutide (Rybelsus)
Therapeutic Area: diabetes mellitus, type 2
Draft recommendations posted for stakeholder feedback: May 13, 2021
End of feedback period: May 28, 2021
Draft Recommendation
luspatercept (Reblozyl)
Therapeutic Area: beta-thalassemia associated anemia
Draft recommendations posted for stakeholder feedback: May 13, 2021
End of feedback period: May 28, 2021
Draft Recommendation
dupilumab (Dupixent)
Therapeutic Area: Asthma
Draft recommendations posted for stakeholder feedback: May 13, 2021
End of feedback period: May 28, 2021
Draft Recommendation
risdiplam (Evrysdi)
Therapeutic Area: Spinal muscular atrophy
Draft recommendations posted for stakeholder feedback: May 13, 2021
End of feedback period: May 28, 2021
Draft Recommendation
fedratinib (Inrebic)
Therapeutic Area: Myelofibrosis
Draft recommendations posted for stakeholder feedback: May 7, 2021
End of feedback period: May 21, 2021
Draft Recommendation
larotrectinib (Vitrakvi)
Therapeutic Area: Solid tumors with NTRK gene fusion
Draft recommendations posted for stakeholder feedback: May 7, 2021
End of feedback period: May 21, 2021
Draft Recommendation